GIC 1002

Drug Profile

GIC 1002

Alternative Names: GIC-1002; Non-H2S releasing tosylate salt - gIcare Pharma

Latest Information Update: 06 Apr 2016

Price : $50

At a glance

  • Originator gIcare Pharma
  • Class Opioid analgesics
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Procedural pain

Most Recent Events

  • 01 Dec 2014 gIcare Pharma completes a phase I trial in Healthy volunteers (NCT02276768)
  • 01 Oct 2014 Phase-I clinical trials in Procedural pain (In volunteers) in Canada (PO) (NCT02276768)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top